Recombinant MUC16 (Sofituzumab Biosimilar) 抗体
The Mammalian Cells 单克隆 anti-MUC16 (Sofituzumab Biosimilar) antibody (ABIN7488033) specifically detects MUC16 (Sofituzumab Biosimilar) in ELISA.
The antibody is reactive with 人 samples.
产品编号 ABIN7488033
发货至:
中国
Contact our Customer Service for availability and price in your country.
Contact Info
Our Local Distributor
中国
北京 101111
北京 101111
No. 88 KeChuang 6th Street
Beijing Economic Technological Development Area
Room 801-803
Quick Overview for Recombinant MUC16 (Sofituzumab Biosimilar) 抗体 (ABIN7488033)
抗原
MUC16 (Sofituzumab Biosimilar)
抗体类型
Recombinant Antibody
适用
人
宿主
Mammalian Cells
克隆类型
单克隆
标记
This MUC16 (Sofituzumab Biosimilar) antibody is un-conjugated
应用范围
ELISA
质量等级
Research Grade
-
-
Expression System
- Mammalian cells
-
原理
- Sofituzumab Biosimilar - Anti-MUC16, CA125 mAb
-
产品特性
- Antibody Type: IgG1-kappa
-
纯化方法
- Recombinant antibody expressed in mammalien cells and purified.
-
亚型
- IgG1 kappa
-
-
-
-
限制
- 仅限研究用
-
-
-
缓冲液
- PBS pH 7.5
-
储存条件
- -80 °C
-
储存方法
- store at -80°C
-
-
- MUC16 (Sofituzumab Biosimilar)
-
物质类
- Biosimilar
-
背景
-
DMUC5754A (conjugate),MMUC1206A (nonconjugate)
Sofituzumab is investigated for the treatment of Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer. Sofituzumab Vedotin (also known as DMUC5754A and RG-7458) is an antibody-drug conjugate (ADC) that contains the humanized IgG1 anti-MUC16 monoclonal antibody (mAb) and a potent anti-mitotic agent, monomethyl auristatin E (MMAE), linked through a protease-labile linker, maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl. DMUC5754A binds to the MUC16 extracellular domain with high affinity, and shows potent and selective anti-tumor activity in MUC16-expressing human ovarian cancer (OC) and pancreatic cancer (PC) mouse xenograft models. The targeted therapeutic strategy of DMUC5754A resulted in enhanced tumor-specific activity of MMAE, while minimizing exposure to tissues that do not express MUC16. -
CAS-编号
- 1418200-58-4
抗原
-
You are here:
